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Neuromyelitis optica (NMO) is an uncommon disease 
that affects the optic nerves and spinal cord1. The recent iden-
tification of a specific antibody for aquaporin 4 (AQP4) wa-
ter channel at the blood-brain barrier in NMO patients (IgG-
NMO) makes it the first central nervous system autoimmune 
channelopathy2.
Little is known about cognitive dysfunction in NMO, its 
frequency, and its relationship with clinical variables. Blanc 
et al.3 reported impairment of attention, speed of information 
processing, and word generation in NMO patients. Nilsson 
et al.4 also found cognitive impairment (CI) in patients diag-
nosed with isolated optic neuritis (ON) from 24 to 31 years 
earlier. Finally, He et al.5 evidenced cognitive alterations in 
NMO patients after an acute relapse, and encountered an as-
sociation between neuropsychological performance and rou-
tine activities6.
During the past 20 years, numerous researches have indi-
cated frequent CI in multiple sclerosis (MS) patients. Working 
memory, attention, verbal fluency, and speed of information 
processing are often affected7-9.
The differences between MS and NMO neuropathology 
suggest distinct cognitive patterns, but only one previous 
study compared these patients and found no significant vari-
ations in cognitive measures3.
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ABSTRACT
The aim of the present research was to investigate cognitive pattern of patients with neuromyelitis optica (NMO) and to compare it with mul-
tiple sclerosis (MS) patients’ performance. Methods: Fourteen NMO, 14 relapsing remitting multiple sclerosis (RRMS), and 14 healthy control 
patients participated in the investigation. Neuropsychological functions were evaluated with the Brief Repeatable Neuropsychological Battery 
for MS; Symbol Digit Modalities Test; Digit Span; and Semantic Fluency. Results: Fifty-seven percent of NMO patients and 42.85% of the MS 
ones had abnormal performance in at least two cognitive tests. The NMO Group showed abnormal performance in verbal fluency, verbal and 
visual memories, with greater attention deficits. NMO patients outperformed healthy control in the paced auditory serial addition test (PASAT). 
However, no difference was found between NMO and RRMS patients. Conclusions: The NMO Group showed more dysfunction in attention and 
verbal fluencies than in verbal and visual memories. When compared with the MS patients, a similar dysfunction pattern was found.
Key words: neuropsychology, neuromyelitis optica, depression, multiple sclerosis, autoimmune diseases.
RESUMO
O objetivo da presente pesquisa foi investigar o padrão cognitivo de pacientes com neuromielite óptica (NMO) e compará-lo com o desem-
penho de pacientes com esclerose múltipla (EM). Métodos: Quatorze pacientes com NMO, 14 com esclerose múltipla recorrente remitente 
(EMRR) e 14 participantes do Controle saudáveis  participaram da presente investigação. As funções neuropsicológicas foram avaliadas com 
a Bateria Breve de Testes Neuropsicológicos de Rao, Teste Símbolo Digit e a Fluência Semântica. Resultados: Cinquenta e sete por cento dos 
pacientes com NMO e 42,85% daqueles com EM apresentaram desempenho anormal em pelo menos dois testes cognitivos. O Grupo NMO 
apresentarou desempenho anormal na fluência verbal e nas memórias visual e verbal, com maiores déficits de atenção. Pacientes com NMO 
superaram os controles saudáveis em PASAT. No entanto, não foi encontrada diferença entre os pacientes com NMO e aqueles com EMRR. 
Conclusões: O Grupo NMO mostrou mais disfunção nas fluências de atenção e verbais do que nas memórias verbal e visual. Quando compa-
rados com os pacientes com EM, um padrão de disfunção semelhante foi encontrado.
Palavras-Chave: neuropsicologia, neuromielite óptica, depressão, esclerose múltipla, doenças autoimunes.
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The aim of the present study was to describe the cogni-
tive pattern of NMO patients and compare it with that of MS 
ones, considering pathophysiological mechanisms, diagnos-
tic criteria, evolution, and treatments of these diseases.
METHODS
Participants
Fourteen patients diagnosed with NMO, 14 with relapsing 
remitting MS (RRMS), and 14 healthy controls were evaluat-
ed. Twelve females and 12 males were recruited in all groups. 
NMO patients were diagnosed in the Neurology Service at 
the J. M. Ramos Mejia Hospital, Buenos Aires, Argentina. The 
RRMS patients were selected, considering gender, age, and ed-
ucation to match them with NMO participants: (±) 3 in age 
and (±) 2 in education. The inclusion or exclusion criteria were: 
confirmed diagnosis as defined by Wingerchuk’s10 in the NMO 
Group, and as by McDonald’s of RRMS; 18 years or older; being 
in remission period; absence of psychiatric illness; history of 
alcohol or drug abuse; no physical disability that could impair 
performance of tests; no uncontrolled systemic disease or that 
could cause cognitive impairment. Healthy controls without 
history of neurological disease and mini mental state exami-
nation (MMSE) scores >26 were also recruited.
Standard protocol approvals, registrations, and 
patient consents
This study was approved by the J. M Ramos Mejia Hospital 
Bioethical Committee, and all participants signed an in-
formed consent.
Outcome measures
Physical disability was measured through the Expanded 
Disability Status Scale (EDSS)11. The Brief Repeatable Battery 
of Neuropsychology Tests (BRB-N)12, translated into Spanish 
and culturally adapted to this Latin American population9, 
was administered by a trained neuropsychologist. The pro-
cedure started with six learning trials from a brief version of 
the Selective Reminding Test (SRT), from which measures of 
learning (long-term storage or LTS) and consistency of recall 
(consistent long-term retrieval or CLTR) were derived. Next, 
a visual/spatial memory test, the 7/24 Spatial Recall Test, 
was administered. The Rao version of the Paced Auditory 
Serial Addition Task (PASAT) was then completed, requiring 
rapid calculations and divided attention. The Word List 
Generation (WLG) test and the oral version of the Symbol 
Digit Modalities Test (SDMT)13 were administered prior to 
the delayed recall testing.
The test 7/24 Spatial Recall and SDMT were not managed 
in three patients due to visual impairments.
Beck’s Depression Inventory II (BDI-II)14 was carried out 
as a depression measure.
Procedure
All patients underwent a complete neurological exami-
nation. The neurologist scored the EDSS and registered de-
mographic and clinical data, such as age, education, and du-
ration of the disease. NMO ones underwent brain magnetic 
resonance imaging (MRI) examination with and without con-
trast (sequences T1, T2, and FLAIR, performed in a 1.5-Tesla 
resonator according to the MS protocol of the consortium)15.
Statistical analysis
Data analysis was performed using the Statistical Package 
for the Social Sciences (SPSS), version 16.0 (IBM). Inferential 
calculations were performed using analysis of variance 
(ANOVA), Pearson’s r correlations, and logistic regression anal-
ysis. The level chosen for alpha was 0.05. Patients with two or 
more affected domains (verbal memory – SRT; visual memo-
ry – 7/24 visual spatial; verbal fluency – controlled oral world 
association (COWA); attention – PASAT) were considered cog-
nitively impaired. Scores in a cognitive domain below the fifth 
percentile of normal values9 were considered abnormal.
RESULTS
No significant differences were found between the 
groups with respect to age (p=968) or education (p=553). 
Furthermore, the NMO and MS Groups did not differ in 
the EDSS (p=0.114) or disease duration (p=0.367). Data are 
shown in Table 1.
Regarding the ANOVA, there was a major significant ef-
fect among the groups on SRT-CLTR (p=0.04), SRT delayed 
recall (p=0.048), PASAT-2 seconds (p=0.004), and COWA 
(p=0.043). Following a posteriori Tukey’s tests, the NMO pa-
tients performed significantly worse than the controls in 
PASAT-2 (p=0.003). The MS Group had a worse performance 
than the controls on SRT-LTR (p=0.034), SRT delayed recall 
NMO MS Healthy Controls
p-value
n=14 n=14 n=14
Mean age (years) 36.86±12.42 37.93±10.57 37.07±12.39 ns
Mean instruction level (years) 11.26±3.29 12.79±3.55 11.86±4.07 ns
Mean disease course (years) 8.62±4.35 6.62±6.52 ns
Mean EDSS 4.31±2.59 2.2±1.68 ns
Table 1. Demographic and clinical data of neuromyelitis optica and multiple sclerosis patients and healthy controls.
NMO: neuromyelitis optica; MS: multiple sclerosis; EDSS: expanded disability status scale.
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(p=0.048), and 7/24 Correct Answers Trails 1 to 5 (p=0.048). 
However, no differences were found between the NMO and 
MS Groups, which can be seen in Table 2.
When comparing the performance of NMO patients with 
local normative scores, it was found that 35.71% of them 
showed abnormal performance in verbal memory, 9.09% had 
some problem in visual memory, 64.28% had in attention, 
and 48.85% presented abnormal performance in verbal flu-
ency. In the MS Group, 61.53% of the participants showed ab-
normal performance in verbal memory, 61.53% had problem 
in visual memory, 33.33% in attention, and 38.46% showed 
abnormal performance in verbal fluency. 
Characteristic of the Neuromyelitis optica Group
Considering the amount of impaired tests (35.71%), the 
sum of these percentages exhibited no alteration (7.14%), 
had one impaired test (28.57%), had two impaired tests, and 
(28.57%), had three or more impaired tests.
Regarding association between MRI and the amount of 
impaired tests, five out of eight patients with a normal MRI 
and four out of six with lesions had at least one cognitive im-
paired test. Comparison of cognition among patients with 
and without lesions using MRI revealed a significant differ-
ence only in one test, namely SRT-CLTR (p=0.016), therefore 
patients without lesions (n=7) performed better than those 
with such thing. Concerning the levels of depression, eight 
subjects showed score within the normal range (Grade  1), 
while six revealed signs of depression; one showed mild de-
pression (Grade 2), three presented moderate depression 
(Grade 3), whereas the remaining three had severe depres-
sion (Grade 4). The data are summarized in Table 3.
Correlations between the neuropsychological mea-
sures and BDI-II and demographics variables are presented 
in Table 4. BDI-II correlated significantly and negatively to 
PASAT-3 (r=-0.652, p<0.05) and PASAT-2 (r=-0.688, p<0.01). 
However, the BDI-II scores did not correlate significantly 
with EDSS or disease duration. Furthermore, scores on SRT 
delay recall and PASAT-3 test were significantly correlated to 
age and education. However, cognitive tests did not correlate 
to evolution disease and EDSS (data not shown).
Test store NMO MS HC p-value
SRT-LTR 40.50± 20.53 37.62±11.75 49.79±13.98 0.128
SRT-CLTR 28.50±17.20 22.69±13.73 38.36±15.45 0.040
SRT-Delayed recall 7.29±3.14 6.62±2.95 9.21±2.00 0.048
7/24-Correct answers trails 1 to 5 26.82±5.05 22.46±6.96 28.50±6.68 0.054
7/24-Immediate recall 5.64±1.50 4.42±2.42 5.29±1.93 0.328
7/24-Delayed recall 5.55±1.57 4.25±1.91 5.93±1.81 0.060
PASAT-3” 31.36±18.36 38.25±15.53 41.86±12.16 0.208
PASAT-2” 21.36±15.12 26.92±9.54 37.86±11.52 0.004
COWA 28.07±12.12 29.23±7.44 38.08±11.89 0.043
Symbol digit modalities test 43.00±10.75 37.85±14.53 46.07±8.09 0.187
BDI-II 18.30±11.09 11.90±8.22 5.42±4.51 0.001
Table 2. Neuropsychological test results for the neuromyelitis optica and multiple sclerosis patients and healthy controls.
NMO: neuromyelitis optica; MS: multiple sclerosis; HC: healthy controls; SRT: selective reminding test; LTR: long-term storage; CLTR: consistent long-term 
retrieval; PASAT: paced auditory serial addition test; COWA: controlled oral word association; BDI-II: Beck depression inventory II.
Patient number Brain MRI BDI-II
Cognitive domains
Verbal memory Visual memory Verbal fluency Attention
1 Normal 1 0 0 0 1
2 Unspecific lesions 3 1 0 1 1
3 Normal 1 0 1 0 1
4 Normal 4 0 0 1 1
5 Typical lesions AQP4 2 0 0 0 0
6 Unspecific lesions 3 1 0 0 1
7 Normal 1 0 0 0 0
8 Typical lesions AQP4 1 1 0 1 1
9 Unspecific lesions 1 0 0 0 0
10 Normal 1 0 0 0 0
11 Normal 1 1 NA 1 1
12 Normal 1 0 0 0 0
13 Normal 4 0 NA 1 1
14 Unspecific lesions 4 1 NA 1 1
MRI: magnetic resonance imaging; BDI: Beck depression inventory; AQP4: Aquaporin 4; cognitive domains=0: within normal range, 1: below the fifth percentile, 
NA: not applied visual alterations; BDI II=grades 1: 0 to 13 (without depression); 2: 14 to 19 (mild); 3: 20 to 28 (moderate); 4: 29 to 63 (severe).
Table 3. Individual neuropsychological results of neuromyelitis optica.
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Table 4. Correlations between neuropsychological measures, 
depression, age, and education in neuromyelitis optica patients.
BDI-II Age Education
r-value r-value r-value
SRT-LTR -0.223 -0.318 0.522
SR-CLTR -0.156 -0.390 0.565*
SRT-Delayed recall -0.243 -0.577* 0.771**
7/24-Correct answers 
trails 1 to 5
-0.006 -0.054 0.056
7/24-Immediate recall 0.231 0.279 -0.047
7/24-Delayed recall -0.469 -0.277 -0.110
PASAT 3” -0.652* -0.631* 0.679**
PASAT 2” -0.688** -0.464 0.503
COWA -0.549 -0.572* 0.765**
SRT: selective reminding test; LTR: long-term storage; CLTR: consistent long-
term retrieval; PASAT: paced auditory serial addition test; COWA: controlled 
oral word association; BDI-II: Beck depression inventory II; *p<0.05 level; 
**p<0.01 level.
DISCUSSION
NMO patients presented a significantly lower neuro-
psychological performance than healthy controls of similar 
age and education. Surprisingly, 57.14% of the NMO Group 
showed CI. Similarly, Blanc et al.3 found 56.7% of CI in their 
sample and He et al.5 also reported it.
Regarding cognitive performance, the few descriptions 
found in the literature on patients with NMO accounted a 
pattern of subcortical cognitive impairment, characterized 
by reduced speed of information processing, changes in ex-
ecutive functions, attention, and memory. In this research, 
the NMO Group showed more dysfunction in attention and 
verbal fluency than in memory. Blanc et al.3 described alter-
ation of long-term memory and executive functions, while 
He et al.5 found memory deficit and decreased speed of in-
formation processing and attention, after an acute relapse. 
This stage of the disease might not be the most appropriate 
for the evaluation of patients, because many factors involved 
in the pathogenesis of a relapse go beyond those involved in 
that of the disease itself.
Cognitive performance of NMO patients was found to 
be similar to that of MS ones coinciding with Blanc et al.3. 
However, when compared with the published local norms, 
a higher proportion of MS patients showed visual memory 
impairment and a higher proportion of the NMO Group ev-
idenced attention issues. Furthermore, CI in NMO patients 
could be considered surprising, since NMO is thought to be 
restricted to damage of optic nerves and spinal cord.
At the early stage of the disease, MRI brain lesions are al-
most inexistent, with a few exceptions of little subcortical 
white matter lesions. However, recent MRI and pathological 
anatomy findings suggest that tissue damage in NMO is more 
extensive and includes the compromise of other areas, such 
as brain stem, cerebellum, and cortex16-18. Although this study 
was not meant to examine the relationship between cogni-
tion and MRI findings, cognitive alterations were found both 
in patients with and without lesions in MRI. He et al.5 reported 
evidence of microscopic brain lesions using diffusion tensor 
imaging, which could explain the presence of cognitive altera-
tions in those without lesions in conventional MRI measures. 
A high number of patients (6 out of 14) manifested 
signs of depression, ranging from mild to severe, coincid-
ing with the findings of Chanson et al.19, who found influ-
ence of depression on the quality of life of patients with 
NMO. Moreover, He et al.6 reported a significant correla-
tion between cognition, depression, and routine activities 
in patients assessed after an acute relapse of the disease. 
Depression was related to attention measures, but not with 
physical disability or disease durations. The negative influ-
ence of depression in attentional functions has already been 
reported in MS20. In NMO, Blanc et al.3 did not observe an 
association between cognition and depression. 
Cognition is not associated with physical disability and 
disease duration, this is consistent with the findings of Blanc 
et al.3. The limitations of this study include the administra-
tion of neuropsychological test with a visual component and 
the lack of control of symptomatic pharmacological treat-
ments. Studying a larger group of patients would be needed 
to improve the description of cognitive pattern, as well as the 
impact on patients’ quality of life. In future, longitudinal re-
search will shed light on the evolution of cognitive disorders 
and possible predictors of this symptom in NMO.
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